• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

CMS Provides Billing Code for Pepaxto

News
Article

The multiple myeloma therapy now has a permanent J code under Medicare Part B.

The Centers for Medicare and Medicaid Services (CMS) has provided a permanent J code for Pepaxto (melphalan flufenamide). J codes are product-specific reimbursement codes assigned to outpatient and physician administered “buy and bill” products under Medicare Part B. Claims submission and payment are standardized with a J code. The Code, J9247, “injection, melphalan flufenamide, 1mg” will go into effect on October 1, 2021.

"Having a permanent J code will help to ease the administrative burden of billing for our drug in hospitals as well as community clinics,” Mohamed Ladha, general manager of Oncopeptides’ U.S. business unit, said in a statement. Oncopeptides is a Swedish company that is marketing Pepaxto in the U.S. “This J code will help to increase reimbursement confidence among providers and their practice management staff and enable more eligible patients to gain access to therapy.”

The FDA approved Pepaxto in February 2021 in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease. Pepaxto is the first anticancer peptide-drug conjugate approved by the FDA. The product has been granted accelerated approval based on the phase 2 HORIZON study in relapsed or refractory multiple myeloma.

In March, the National Comprehensive Cancer Network (NCCN) included Pepaxto on the new Multiple Myeloma Clinical Practice Guidelines. NCCN is an alliance of 30 cancer centers in the United States that issues influential guidelines for cancer treatment.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.